Moore for Hema Health

19/10/2026

Really exhilarating to share the clinical update that 44 of our cohorts participated in our gene therapy trial to back up strongly on our efficacy as well as our safety over the long term study and assessment.
Regional approved and available in China, this provides an excellent alternative to patients seeking for potential cure and freedom from chronic blood transfusion.
DM me for details and info on our Kanexthal for Transfusion dependent thalassemia

🔬 Research Spotlight | KL003 Clinical Data at EHA 2026

Advancing gene therapy through clinical research and scientific exchange.

At the European Hematology Association (EHA) Congress 2026, clinical research on KL003, a gene-modified autologous hematopoietic stem cell therapy for β-thalassemia, was presented by Peihong Wang and colleagues.

The presentation contributes to the growing body of scientific evidence exploring gene therapy as a potential treatment approach for patients with β-thalassemia.

At Kanglin Biotec, we remain committed to advancing innovative gene therapies through clinical research, scientific collaboration, and the continued evaluation of long-term treatment outcomes.

📖 Explore the research presented at EHA 2026:
https://library.ehaweb.org/eha/2026/eha-2026/4207125/peihong.wang.gene-modified.autologous.hematopoietic.stem.cell.therapy.for.html

16/10/2026

Thank You, Egypt!
On October 13, Kanglin Biotec hosted an educational webinar on gene therapy for beta-thalassemia, connecting with healthcare professionals and members of Egypt's thalassemia community.

Our speaker, Dr. Wei Tan, shared insights into gene therapy developments, clinical experience, and patient access pathways.

The session featured engaging discussions on treatment safety, patient eligibility, long-term outcomes, and opportunities for future healthcare collaboration.

A big thank you to everyone who joined us and contributed to the discussion!

We look forward to staying connected and continuing to support scientific exchange with the Egyptian healthcare community.

24/09/2026

22/09/2026

Welcome to join and discuss with us!
Aramıza katılmaya ve bizimle tartışmaya davetlisiniz.

Join us for the upcoming webinar: Future Advances in Haemoglobinopathies

We are pleased to share that Dr. Wei Tan, Head of International Business at Kanglin Biotec, has been invited as a speaker to the upcoming “Future Advances in Haemoglobinopathies” webinar on October 2, 2026.

“Current Approaches to Gene Therapies for Thalassemia and Sickle Cell Disease Worldwide”

The webinar will explore current and next-generation approaches in the field of haemoglobinopathies, with discussions covering gene therapy, prime editing, AAV engineering and in vivo hematopoietic stem cell modification.

📅 October 2, 2026
🕝 2:30–5:20 PM CEST (UTC+2)
💻 Online Webinar
🎟️ Free registration

Organizing Secretariat: Biba Group
Register here:
https://www.formeeting.it/fad/iscrizioni.fmp?id=12361&m=1&check=htrwsa&lang=yes&utm_

We look forward to connecting with the global community and contributing to the discussion on advances in gene therapy for thalassemia and sickle cell disease.

14/09/2026

Meet Kanglin Biotec at EGY Health 2026!

We’re excited to share that our colleague Mona (tag Mona)will be representing Kanglin Biotec at EGY Health 2026, taking place from 15–17 September in Egypt.

Mona looks forward to meeting healthcare professionals, hospitals, organizations, and partners from Egypt and across the MENA region, and exchanging ideas on:
🧬 Gene therapy & β-thalassaemia care
🏥 International patient access
🤝 Healthcare partnerships & collaboration

Will you be at EGY Health 2026? Come and connect with Mona!
📅 15–17 September 2026
📍 Egypt

We look forward to seeing you there!

09/07/2026

A milestone in gene therapy manufacturing—and a step forward for patients worldwide. 🧬

On June 30, 2026, Kanglin Biotec officially launched its Gene Therapy Manufacturing Base at Hangzhou Biopharma Town.
This facility represents a transition from clinical-stage development to commercial-scale, GMP-compliant manufacturing.

With this launch, Kanglin Biotec now establishes in-house manufacturing capabilities across the core production chain for cell and gene therapies, including:
🌟Plasmids
🌟Lentiviral vectors
🌟Adeno-associated virus (AAV) vectors
🌟Cell injection formulations

These capabilities are centralized in a single facility, designed and operated in accordance with international GMP standards.

For international patients and their families, this development has practical implications: it supports more predictable supply chains, reduced manufacturing-related delays, and production processes built for regulatory alignment—all essential factors in bringing gene therapies to those in need.

Our commitment remains focused on advancing cell and gene therapy platforms, not only for the Chinese market, but for global patient communities where unmet medical needs persist.

We will continue to share updates on clinical development, regulatory progress, and our efforts to increase access to transformative therapies.

Because every patient deserves a future built on science, quality, and care. 💙

18/06/2026

As we celebrate the Dragon Boat Festival, we wish you a vibrant season filled with the warmth of family, the joy of traditions, and great health!

27/05/2026

Today is Eid Al Adha day. We wish you and your family a joyful and blessed Eid Al Adha. Eid Mubarak! ✨